tbuckley/cabot-search huggingface dataset:
Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study.
Authors: Michael J. Morris, Hans J. Hammers, Christopher Sweeney, Emmanuel S. Antonarakis, Steve Y. Cho, Neeta Pandit-Taskar, Heather Jacene, Marianne Bloma, Anne-Kirsti Aksnes, C. Gillies O'Bryan-Tear, Jorge A. Carrasquillo
Journal: Journal of Clinical Oncology (2013)

5021 Background: Ra-223, a first-in-class α-emitting pharmaceutical, targets bone metastases (mets) with high-energy α-particles of very short range (&lt; 100 µm). D is an approved chemotherapy with demonstrated survival benefit for patients progressing after castrating hormone therapy. We are exploring the hypothesis that simultaneously targeting the tumor and the bone is clinically superior to targeting either alone. We therefore conducted a phase I study of Ra-223 + D in patients with CRPC and bone mets to establish the safety of the combination. Methods: Eligible patients had confirmed symptomatic CRPC with ≥ 2 bone mets and were candidates for treatment with D. Dose escalation followed a 3 + 3 design, with no intrapatient dose escalation or overlapping of cohorts. Patients were to receive 2 combined doses of Ra-223 q6wk + D q3wk (cohort 1: Ra-223/D = 25 kBq/kg /75 mg/m 2 ; cohort 2: Ra-223/D = 25 kBq/kg /60 mg/m 2 ; and cohort 3: Ra-223/D = 50 kBq/kg /60 mg/m 2 ). Dose-limiting toxicity was assessed 6 weeks after first Ra-223 + D injection. Long-term safety data were collected every 3 months after end of study treatment for up to 1 year after start of study treatment. Results: 17 patients were treated, 7 each in cohorts 1 and 3 (1 patient in each cohort discontinued early and was replaced), and 3 in cohort 2. There was no discontinuation or delay of Ra-223 due to adverse events, and so far no reports of long-term toxicity during follow-up. 4 cases of febrile neutropenia occurred during study treatment (12 wk): 3 occurred in cohort 1 (1 was 7 days after first Ra-223 + D, and 2 were in the same subject, both occurring 1 wk after first and second doses of D alone [wk 4 and 10]); 1 occurred in cohort 3, 1 week after second Ra-223 + D (wk 7). Other safety data were as expected based on Ra-223 and D monotherapy data. Conclusions: The phase IIa regimen of Ra-223 + D utilizes a regimen of D 60 mg/m 2 q3wk × 10 + Ra-223 50 kBq/kg q6wk × 5. The regimen is currently being explored in a randomized 2:1 open-label expanded safety cohort comparing Ra-223 + D versus D 75 mg/ m 2 alone (standard dose). Clinical trial information: NCT01106352.
Abstract 14766: Short-Term Dual Antiplatelet Therapy Following Bare Metal Stent Increases the Risk of Ischemic Events- A Meta-Analysis of Randomized Clinical Trials
Authors: Georges El-Hayek, Abel Casso Dominguez, Jacqueline Tamis-Holland, Eyal Herzog, Alexandre Benjo, Sripal Bangalore
Journal: Circulation (2014)

Background: Bare metal stents (BMS) are a reasonable option even in the modern era of superior outcomes with 2nd generation drug eluting stents mainly because of the need for short term dual antiplatelet platelet therapy (DAPT). Current guidelines recommend a minimum of 1 month of DAPT following BMS use. The safety of limiting DAPT to one month has not been clearly established. Methods: We searched PubMed, Scopus and ClinicalTrials.gov databases till May 2014 for randomized clinical trials (RCTs) that compared short (&lt;6 months) versus long DAPT duration (&gt; 6 months) after BMS. Risks ratios (RRs) with 95% confidence interval (CI) for the composite outcome of cardiac death or myocardial infarction (MI) and for major bleeding were calculated using random-effects model. Results: We included 3 RCTs in this analysis. A total of 2654 patients received short term DAPT and 2612 patients received long term DAPT (9 to 24 months). The rates of cardiac death or MI were significantly higher in the short-term DAPT group (9.1%) compared to the prolonged DAPT group (7.0%)which corresponds to a 30% increase in the risk of cardiac death or MI (RR: 1.30, 95% CI: 1.08 to 1.57; p=0.005, figure). On the other hand, short-term DAPT was associated with numerically lower major bleeding events (4.0% vs 5.0%) when compared with prolonged DAPT but this did not reach statistical significance (p=0.06). Conclusion: Short-term DAPT as compared with prolonged treatment is associated with an increased risk of cardiac death or MI.
Spotlight on measles 2010: Ongoing measles outbreak in Greece, January–July 2010
Authors: D Pervanidou, E Horefti, S Patrinos, T Lytras, E Triantafillou, A Mentis, S Bonovas, T Panagiotopoulos
Journal: Eurosurveillance (2010)

A measles outbreak (126 reported cases to date) has been ongoing in Greece, since January 2010, originally related to the recent outbreak in Bulgaria. Cases are mostly unvaccinated, and mainly belong to three groups: Roma population of Bulgarian nationality, Greek Roma population, and Greek non-minority population. In these population groups, 67%, 95%, and 25% of cases respectively were children aged 0-14 years. Measures were taken to raise clinical awareness, and vaccination of specific population groups was undertaken. Policies are necessary to increase routine vaccination uptake of hard-to-reach groups.
EUS-guided fine needle biopsy of pancreatic masses can yield true histology
Authors: Ji Young Bang, Shantel Hebert-Magee, Udayakumar Navaneethan, Muhammad K Hasan, Robert Hawes, Shyam Varadarajulu
Journal: Gut (2017)

As cytological aspirates from endoscopic-ultrasound-guided fine needle aspiration (EUS-FNA) has limited diagnostic sensitivity and are suboptimal for molecular profiling and morphological characterisation of certain neoplasms, a fine needle biopsy (FNB) with three-pronged (Franseen geometry) cutting edge has been developed to procure histology. In a randomised trial of 46 patients with pancreatic masses, procurement of histological core tissue as evidenced by total tissue and tumour areas was significantly higher for 22G FNB than FNA needle. Also, retention of tissue architecture and presence of desmoplastic fibrosis, which are critical for ancillary testing and molecular profiling, respectively, were significantly higher for FNB.

Given the poor outcomes of traditional chemotherapy, there is increased focus on molecular profiling so that pancreatic cancer treatment can be personalised. Pancreatic tissue with architecture containing both tumour cells and desmoplastic stroma is pivotal for molecular analysis. Although EUS-FNA is diagnostically accurate, the cytological aspirate is suboptimal for DNA sequencing.1–3 Therefore, clinical trials evaluating personalised treatment in pancreatic cancer prefer tissue procurement via percutaneous or surgical biopsies over EUS-FNA.4 Recently, a three-plane symmetric needle with Franseen geometry has been developed for performing EUS-guided FNB.5 The large crown-tip with three cutting edges and long insertion length were postulated to facilitate histological tissue procurement (figure 1A). We conducted a randomised trial comparing tissue acquisition between the 22-gauge (G) Franseen biopsy (Acquire, Boston Scientific) and 22G standard bevel FNA (Expect, Boston Scientific) (figure 1B) needles in patients undergoing EUS-guided sampling of pancreatic masses.



Figure 1 
The 22G Franseen design with a crown-shaped needle tip revealing the three symmetrical planes for histological core tissue acquisition (A). The standard bevel needle used at fine needle aspiration for procurement of cytological aspirates (B).



EUS-guided sampling was performed using both needle types, the 22G FNB and 22G FNA needles, with randomisation of the order in which the …
Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141
Authors: L. Licitra, R.L. Ferris, G. Blumenschein, K.J. Harrington, J. Guigay, S. Kasper, N.F. Saba, R. Haddad, N. Kiyota, M. Monga, M. Lynch, L. Li, M.L. Gillison, J. Fayette
Journal: Annals of Oncology (2017)
Follow-up brain imaging of 37 children with congenital Zika syndrome: case series study
Authors: Natacha Calheiros de Lima Petribu, Maria de Fatima Vasco Aragao, Vanessa van der Linden, Paul Parizel, Patricia Jungmann, Luziany Araújo, Marília Abath, Andrezza Fernandes, Alessandra Brainer-Lima, Arthur Holanda, Roberto Mello, Camila Sarteschi, Maria do Carmo Menezes Bezerra Duarte
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To compare initial brain computed tomography (CT) scans with follow-up CT scans at one year in children with congenital Zika syndrome, focusing on cerebral calcifications. <b>Design</b>&nbsp;Case series study. <b>Setting</b>&nbsp;Barão de Lucena Hospital, Pernambuco state, Brazil. <b>Participants</b>&nbsp;37 children with probable or confirmed congenital Zika syndrome during the microcephaly outbreak in 2015 who underwent brain CT shortly after birth and at one year follow-up. <b>Main outcome measure</b>&nbsp;Differences in cerebral calcification patterns between initial and follow-up scans. <b>Results</b>&nbsp;37 children were evaluated. All presented cerebral calcifications on the initial scan, predominantly at cortical-white matter junction. At follow-up the calcifications had diminished in number, size, or density, or a combination in 34 of the children (92%, 95% confidence interval 79% to 97%), were no longer visible in one child, and remained unchanged in two children. No child showed an increase in calcifications. The calcifications at the cortical-white matter junction which were no longer visible at follow-up occurred predominately in the parietal and occipital lobes. These imaging changes were not associated with any clear clinical improvements. <b>Conclusion</b>&nbsp;The detection of cerebral calcifications should not be considered a major criterion for late diagnosis of congenital Zika syndrome, nor should the absence of calcifications be used to exclude the diagnosis.
Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)
Authors: M.M. Laterza, V. Ciaramella, F. Morgillo, V. Belli, G. Tirino, L. Pompella, A. Petrillo, B. Savastano, A. Pappalardo, M. Orditura, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2017)
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
Authors: M. Di Maio, C. Baratelli, P. Bironzo, F. Vignani, E. Bria, E. Sperti, M. Marcato, F. Roila
Journal: Annals of Oncology (2017)
Clusters of travel associated legionnaires' disease in France, September 2001- August 2003
Authors: B Decludt, C Campese
Journal: Eurosurveillance (2004)

Clusters of travel associated legionnaires' disease warrant urgent attention, and are detected by the French national surveillance system and the European network EWGLINET. Between September 2001 and August 2003, 37 clusters were identified in French tourist accommodation: 27 hotels and 10 campsites. The number of clinical cases per cluster was as follows: 30 clusters of 2 cases (81%), 6 clusters of 3 cases (16%) and one cluster of 4 cases (3%), a total of 82 cases. The local health authorities performed environmental investigations for 36 of the 37 clusters. Among the 36 clusters investigated, water samples were collected for 35. At 16 (46%) sites, Legionella pneumophila was found at a level of more than 103 cfu/litre. In all of the accommodation where risk assessment was found to be inadequate- control measures were implemented immediately. Six hotels were closed immediately following cluster alerts. Comparison of clinical and environmental isolates by pulsed field gel electrophoresis (PFGE) was possible in 3 clusters and identical genomic profiles of the isolates were found in all. During this two year period of surveillance, we found that on many sites there has been a risk of exposure to Legionella. This reinforces the importance of the European surveillance network and the timely notifications of all the cases to EWGLINET.
T-Cell Receptor Signaling Pathway Exerts a Negative Control on Thrombin-Mediated Increase in [Ca2+]i and p38 MAPK Activation in Jurkat T Cells: Implication of the Tyrosine Kinase p56Lck
Authors: Laurence Maulon, Sandrine Guérin, Jean-Ehrland Ricci, Dariush FarahiFar, Jean-Philippe Breittmayer, Patrick Auberger
Journal: Blood (1998)
EGFR testing scenario across 111 centres in India: A questionnaire-based survey.
Authors: Kumar Prabhash, Purvish M. Parikh, Senthill J Rajappa, Vanita Noronha, Amit Joshi, Shyam Aggarwal, Shailesh Arjun Bondarde, Shekar Patil, Chirag Jyotiker Desai, Rajesh Naik, Sohit Anand, Raju Titus Chacko, Ghanashyam Biswas, Tarini Prasad Sahoo, Deepak Dabkara, Vijay Maruti Patil, Chandrakanth MV, Pratap Kishore Das, Ashok K. Vaid, Dinesh Doval
Journal: Journal of Clinical Oncology (2017)

e13111 Background: Lung cancer diagnosis now involves routine use of biomarker testing to identify the driver mutations. We conducted a survey of 111 medical oncologists across India to understand the current pattern of EGFR mutation testing at their respective centres. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a structured questionnaire. They were divided into two groups - Group 1 with in-house EGFR testing and Group 2 who send samples to central/commercial labs. Answers of the two groups were analysed to see the prevailing patterns of EGFR mutation testing and differences between the groups if any. Results: In India, 95% of medical oncologists recommend testing for EGFR mutations in patients with adenocarcinoma histology. 40% would also recommend testing in squamous histology. 80% of medical oncologists request for biomarker testing at the time of primary biopsy. From the time of biopsy, the average time duration to get EGFR test results is 18 days. In centres with in-house testing (Group 1), results are available in 10 days. 96% of the medical oncologists from Group 1 centres request for factoring additional sample for biomarker testing compared to only 69% from Group 2. 69% of medical oncologists in Group 1 centres would prefer to wait for the test results before initiating treatment compared to 46% in Group 2. EGFR TKIs are used in 60% of patients with diagnosed EGFR mutation in the first line. For patients in whom chemotherapy is initiated while waiting for test results, 50% of medical oncologists prefer completing 4-6 cycles before switching to targeted therapy. At the time of progression, rebiopsy is possible in 25% of the patients. Rapid disease progression and poor PS were the two most common reasons given for the low rebiopsy rates. Conclusions: Application of molecular testing is ‎improving. Yield can be improved by training of multidisciplinary team involved in tumor biopsy. There is scope and need to reduce the turnaround time. This will reduce the current scenario of commencing chemotherapy while waiting for test results. Increasing application of liquid biopsy will help in initial diagnosis as well as at relapse, especially for patients with poor PS or difficult access to tumor site.
DNA and RNA analysis of intratumour heterogeneity in metastatic clear cell renal cell carcinoma
Authors: P. Ferronika, J. Hof, G. Kats-Ugurlu, M. Terpstra, K. De Lange, A. Leliveld-Kors, R.H. Sijmons, K. Kok
Journal: Annals of Oncology (2017)
Bone marrow stroma cells derived from mononuclear cells at diagnosis as a source of germline control DNA for determination of somatic mutations in acute myeloid leukemia
Authors: H Mujahed, M Jansson, S Bengtzén, S Lehamnn
Journal: Blood Cancer Journal (2017)

Bone marrow stroma cells derived from mononuclear cells at diagnosis as a source of germline control DNA for determination of somatic mutations in acute myeloid leukemia
Effects of the fibrous topography-mediated macrophage phenotype transition on the recruitment of mesenchymal stem cells: An in vivo study
Authors: Qiankun Zhang, Jin Wook Hwang, Joung-Hwan Oh, Chan Ho Park, Shin Hye Chung, Yun-Sil Lee, Jeong-Hwa Baek, Hyun-Mo Ryoo, Kyung Mi Woo
Journal: Biomaterials (2017)
Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid‐range and preserved ejection fraction
Authors: David M. Kaye, Frank E. Silvestry, Finn Gustafsson, John G. Cleland, Dirk J. van Veldhuisen, Piotr Ponikowski, Jan Komtebedde, Shane Nanayakkara, Dan Burkhoff, Sanjiv J. Shah
Journal: European Journal of Heart Failure (2017)
Epidémiologie de la rubéole et du syndrome de rubéole congénitale en Grèce, 1994-2003
Authors: T Panagiotopoulos, T Georgakopoulou
Journal: Eurosurveillance (2004)

En 1993, une vaste epidemie de rubeole et de syndrome de rubeole congenitale (SRC) a eu lieu en Grece. L'epidemiologie de la rubeole et du SRC, depuis 1993, decrite dans cet article, est basee sur des donnees de surveillance et des etudes et rapports publies. Apres 1993, l'incidence de la rubeole a fortement decru, mais une epidemie plus reduite a eu lieu en 1999, touchant essentiellement les jeunes adultes et quatre cas de SRC (4,0 pour 100 000 naissances d'enfants vivants) ont ete notifies. En Grece actuellement, une proportion tres importante des enfants sont vaccines contre la rubeole, alors que la couverture vaccinale des adolescents est insuffisante (60-80% selon diverses etudes). Une proportion non negligeable de femmes en âge de procreer sont susceptibles a la rubeole (10-20% dans les zones urbaines). De ce fait, il existe un risque d'epidemies locales ou plus etendues. Cette situation montre l'importance d'une politique globale de prevention.
Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients.
Authors: Mugdha Anand Deo
Journal: Journal of Clinical Oncology (2014)

3060 Background: Uveal melanoma is the most common intraocular malignant tumor with an incidence of approximately 5 cases per million per year. Around 50% of the patients relapse after a curative-intended local treatment. Liver metastasis is the most common site of recurrence. The standard treatment is a systemic chemotherapy with an alkylating agent but does not show an overall survival benefit. In this study, we assessed the overall survival benefit from ipilimumab treatment in metastatic uveal melanoma (MUM) patients based on its success in improving overall survival in cutaneous melanoma patients. Methods: A retrospective analysis was performed at the Cliniques Universitaires Saint-Luc to assess the long term survival benefit from ipilimumab treatment in previously treated MUM patients. The patients progressing after a first-line chemotherapy were sequentially included if their ECOG score was ≤ 2. They received 3mg/kg of ipilimumab every 3 weeks with the median cycle number of 3.92. Tumor response was assessed every 3 months using CT scan according to RECIST. Progression free survival (PFS), overall survival (OS) and objective response (OR) were calculated using Kaplan-Meier and median duration of follow-up was calculated by univariate analysis. Results: Twenty-four previously treated MUM patients were included in this analysis. No OR was observed in 23 (96%) patients, while 1(4%) patient showed a late partial response after 9 months. Four (17%) patients showed a stable disease lasting ≥ 3 months. With a median follow-up of 7.3 months, the median PFS was 2.8 months. The median OS was 9.7 months and OS rates at 12 and 24 months were 45.6% and 11.4%, respectively. Conclusions: Our findings confirm the very low response rate of ipilimumab in MUM patients. However, this drug has a clear benefit in increasing the overall survival for some patients than that obtained with standard chemotherapy. Most of the published data assessing the efficacy of ipilimumab in ocular melanoma are focused on response rate and median overall survival. We do think that looking at the survival rate at 1-2 years is more relevant to assess the efficacy of ipilimumab. How to select patients benefiting from ipilimumab remains a challenge.
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer
Authors: J.V. Schou, F.O. Larsen, B.S. Sørensen, R. Abrantes, A.K. Boysen, J.S. Johansen, B.V. Jensen, D.L. Nielsen, K.L. Spindler
Journal: Annals of Oncology (2017)
GW28-e1226 Left Atrial Diameter has good predictive valve on Left Atrial Thrombus or Left Atrial Spontaneous Echo Contrast in Non-valvular Atrial Fibrillation Patients with low-moderate risk of stroke
Authors: Lin Weidong, Xue Yumei, Fang Xianhong, Zhan Xianzhang, Liao Hongtao, Liu Fangzhou, Wu Shulin
Journal: Journal of the American College of Cardiology (2017)
18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy
Authors: Paola Mapelli, Flavia Zerbetto, Elena Incerti, Gian Marco Conte, Valentino Bettinardi, Federico Fallanca, Nicoletta Anzalone, Nadia Di Muzio, Luigi Gianolli, Maria Picchio
Journal: Clinical Nuclear Medicine (2017)

A 57 year-old man underwent MRI with dynamic susceptibility contrast and dynamic contrast-enhanced perfusion for neurological symptoms suggesting the diagnosis of high-grade glioma. A F-FAZA PET/CT was performed because of the enrollment in a prospective clinical trial. Subsequent radiotherapy treatment has been planned based on conventional imaging; moreover, a F-FAZA PET/CT-guided treatment planning highlighting hypoxic regions has been simulated. After radiotherapy treatment, the man underwent MRI and F-FAZA PET/CT, showing partial response.
Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
Authors: T. Liu, J. Li, J. Xu, L. Wang, Y. Cheng, W. Chen, J. Chen, C.P. Pescott, S. Qin
Journal: Annals of Oncology (2017)
A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Qi Yang, Meng-Xia Zhang, Xiong Zou, You-Ping Liu, Rui You, Tao Yu, Rou Jiang, Yi-Nuan Zhang, Jing-Yu Cao, Ming-Huang Hong, Qing Liu, Ling Guo, Tie-Bang Kang, Xiao-Feng Zhu, Ming-Yuan Chen
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Metastasis is one of the most important causes of treatment failure in nasopharyngeal carcinoma (NPC). In T4 or N2-3 patients at high-risk of metastasis, concurrent chemoradiotherapy (CCRT) is inadequate and additional induction chemotherapy (IC) is controversial. There is a critical need to develop a better patient stratification to efficiently identify patients at high-risk of metastasis for additional IC. Recently, Sequestosome 1 (SQSTM1)/p62, an autophagy adaptor protein, was identified as one of the metastasis-related proteins in NPC. However, the mechanism by which SQSTM1 is involved in NPC metastasis was not investigated. Experimental Design: The effect of SQSTM1 on cell migration and invasion was examined in vitro and in vivo. SQSTM1 expression was analyzed in clinical NPC samples using IHC. Luciferase reporter analyses were conducted to identify the effects of SQSTM1 on NF-κB transcriptional activity. A prediction bio-model was constructed by Cox analysis. Retrospective and prospective randomized clinical data were adopted to build and test the model, respectively. Results: SQSTM1 mediated epithelial to mesenchymal transition (EMT) through the NF-κB pathway to promote NPC metastasis. Inhibiting SQSTM1 enhanced sensitivity to cisplatin in NPC cells. In NPC patients, high SQSTM1 expression was associated with increased risk of distant metastasis. Furthermore, we propose a prognostic bio-model based on SQSTM1 and N-stage to predict NPC metastasis. Most importantly, our prospective randomized study suggested that IC is beneficial for NPC patients with high metastasis risk. Conclusions: The prognostic bio-model identifies NPC patients at high-risk of metastasis for additional IC. Clin Cancer Res; 24(3); 648–58. ©2017 AACR.